Prostate Cancer
Efficacy of androgen deprivation therapy examined
Published in Drug Week, July 8th, 2005
According to recent research from the United States, "Patients with prostate cancer are treated with neoadjuvant, adjuvant and intermittent therapy with gonadotropin-releasing hormone agonists (GnRH-A). While these are largely successful in decreasing testosterone (T) and dihydroxytestosterone (DHT) to castrate levels, discontinuation of such therapy often results in continued suppression of androgens for variable periods of time."
"We present the largest published series of patients evaluating the timing of T and DHT increase after cessation of GnRH therapy. Serial T and DHT...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-07-08)
More Articles from Drug Week
- Anemia
Exploratory analysis of CERA data shows sustained and stable control of anemia - Cardiovascular Therapy
Valsartan/HCTZ combination is good for patients with added CV risk - Drug Development
Hematide clinical results demonstrate potent effect on red blood cell production - Drug Development
U.S. FDA grants tentative approval of Zolpidem ODT for sleep disorders - Rosacea
Oracea demonstrated up to a 61% reduction in inflammatory lesions in trial - Acetaminophen
Fever control in septic shock examined, benefit or harm probed - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
